UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
RESEARCH & DEVELOPMENT

Adcentrx Therapeutics

Adcentrx Therapeutics logo

Adcentrx Therapeutics

Visit WebsiteContact Company

About Adcentrx Therapeutics

A biotechnology business called Adcentrx Therapeutics is dedicated to quickening the development of novel protein conjugate therapeutics for cancer and other serious illnesses. Adcentrx aims to create the next generation of tailored medicines by fusing the disease-fighting potency of small molecule payloads with the precise targeting of biologics.

Similar Companies

More in Research & Development

4

4DMT

Our "disease first" approach to product discovery and development at 4DMT allows us to tailor our AAV vectors to target particular tissue types linked to the underlying condition. This is made possible by our revolutionary discovery platform, Therapeutic Vector Evolution.

View profile
M

Moderna

In order to develop a new class of revolutionary medications for patients, Moderna is developing the science of messenger RNA (mRNA). mRNA medications are intended to instruct the body's cells to create intracellular, membrane, or secreted proteins that may be useful for therapeutic or preventive purposes and may be used to treat a variety of illnesses. With the help of Moderna's platform, which is built on ongoing developments in basic and applied mRNA science, delivery technology, and manufacturing, the Company is able to explore a strong pipeline of fresh development candidates concurrently. For infectious diseases, immuno-oncology, uncommon diseases, cardiovascular disorders, autoimmune and inflammatory diseases, Moderna is independently and with strategic partners developing medicines and vaccines.

View profile
I

Invizius

Dr. Andy Herbert and Richard Boyd developed the Scottish start-up company Invizius, which uses its unique H-Guard® Priming Solution to lessen the harmful inflammatory effects that dialysis and cardiopulmonary bypass have on patients. Invizius thinks that by applying the solution to extra-corporeal devices like a dialysis filter, patients' blood could enter the device undetected and therefore reduce the inflammatory response. The company is heading its Series A funding round in 2020 and has secured investments from Mercia, Solvay, Downing, Old College Capital, and the Scottish Investment Bank.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy